Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD).

Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, Lonardo A, Malavolti M, Battistini NC, Pellegrini M, Carubbi F, Bellentani S.

Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):353-8. doi: 10.1016/j.clinre.2012.10.009. Epub 2012 Dec 27.

PMID:
23273500
2.

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.

Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, Königsrainer A, Königsrainer I, Kröber S, Niess A, Fritsche A, Häring HU, Stefan N.

Gut. 2009 Sep;58(9):1281-8. doi: 10.1136/gut.2008.151977. Epub 2008 Dec 11.

PMID:
19074179
3.

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P.

Hepatology. 2008 Jul;48(1):119-28. doi: 10.1002/hep.22336.

PMID:
18537181
4.

A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff.

Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, Ushirogawa M, Tsuzura T, Nakashita S, Takahashi H, Kawaguchi Y, Oda Y, Iwakiri R, Ozaki I, Eguchi T, Ono N, Fujimoto K.

J Gastroenterol. 2009;44(12):1203-8. doi: 10.1007/s00535-009-0115-x. Epub 2009 Sep 1.

PMID:
19728009
5.

[Non-alcoholic fatty liver disease and its association with clinical and biochemical variables in obese children and adolescents: effect of a one-year intervention on lifestyle].

Santomauro M, Paoli-Valeri M, Fernández M, Camacho N, Molina Z, Cicchetti R, Valeri L, Dávila de Campagnaro E, Arata-Bellabarba G.

Endocrinol Nutr. 2012 Jun-Jul;59(6):346-53. doi: 10.1016/j.endonu.2012.05.002. Epub 2012 Jun 19. Spanish.

PMID:
22717644
6.

Influence of lifestyle habits, nutritional status and insulin resistance in NAFLD.

Malavolti M, Battistini NC, Miglioli L, Bagni I, Borelli L, Marino M, Scaglioni F, Bellentani S.

Front Biosci (Elite Ed). 2012 Jan 1;4:1015-23.

PMID:
22201932
7.

Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.

Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, Chim AM, Lai JW, Li LS, Sea MM, Chan FK, Sung JJ, Woo J, Chan HL.

J Hepatol. 2013 Sep;59(3):536-42. doi: 10.1016/j.jhep.2013.04.013. Epub 2013 Apr 23.

PMID:
23623998
8.

Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.

Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G.

Clin Ther. 2008 Jun;30(6):1168-76. doi: 10.1016/j.clinthera.2008.06.012.

PMID:
18640473
9.

Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data.

Yki-Järvinen H.

Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):709-14. doi: 10.1097/MCO.0b013e32833f4b34. Review.

PMID:
20842026
10.

Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors.

Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, Jung DH, Kim KH, Yu E, Shim JH, Lim YS, Lee HC, Chung YH, Lee Y, Suh DJ.

J Gastroenterol Hepatol. 2012 Aug;27(8):1341-7. doi: 10.1111/j.1440-1746.2012.07165.x.

PMID:
22554085
11.

Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.

Croci I, Byrne NM, Choquette S, Hills AP, Chachay VS, Clouston AD, O'Moore-Sullivan TM, Macdonald GA, Prins JB, Hickman IJ.

Gut. 2013 Nov;62(11):1625-33. doi: 10.1136/gutjnl-2012-302789. Epub 2012 Oct 17.

PMID:
23077135
12.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K.

N Engl J Med. 2006 Nov 30;355(22):2297-307.

13.

Therapy of nonalcoholic fatty liver disease: current status.

Duvnjak M, Tomasic V, Gomercic M, Smircic Duvnjak L, Barsic N, Lerotic I.

J Physiol Pharmacol. 2009 Dec;60 Suppl 7:57-66. Review.

14.

Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.

Svegliati-Baroni G, Bugianesi E, Bouserhal T, Marini F, Ridolfi F, Tarsetti F, Ancarani F, Petrelli E, Peruzzi E, Lo Cascio M, Rizzetto M, Marchesini G, Benedetti A.

Gut. 2007 Sep;56(9):1296-301. Epub 2007 Mar 28.

15.

Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study.

Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, Younossi ZM.

Aliment Pharmacol Ther. 2012 Oct;36(8):772-81. doi: 10.1111/apt.12038. Epub 2012 Sep 8.

16.

Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.

Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, Foess-Wood L, Sherbondy MA, Conjeevaram HS.

Am J Gastroenterol. 2006 Oct;101(10):2247-53.

17.

The effect of lifestyle changes in non-alcoholic fatty liver disease.

Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G.

Dig Dis. 2010;28(1):267-73. doi: 10.1159/000282101. Epub 2010 May 7. Review.

PMID:
20460922
18.

Non-alcoholic steatohepatitis in children.

Nanda K.

Pediatr Transplant. 2004 Dec;8(6):613-8. Review.

PMID:
15598336
19.

Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C.

Gut. 2011 Oct;60(10):1394-402. doi: 10.1136/gut.2010.222844. Epub 2011 Jan 26.

PMID:
21270117
20.

Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance.

Trovato GM, Martines GF, Trovato FM, Pirri C, Pace P, Garozzo A, Castro A, Catalano D.

Dig Dis Sci. 2012 Feb;57(2):535-44. doi: 10.1007/s10620-011-1903-8. Epub 2011 Sep 28.

PMID:
21953137

Supplemental Content

Support Center